A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

IMPACT REPORT 2018 – 2019 PATIENT STORY: MEET BRUCE SCAFE On the day after Bruce’s 60th birthday, he ran his very first marathon. It was months of training for the […]

Dr. Adrian Lau, Dr. Rowena Ridout, Dr. Claudia Gagnon, Dr. Zahra Bardai, and Dr. Emma Billington. Recommendations from Osteoporosis Canada Rapid Response Team. The Canadian Centre on Substance Use and […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

Introducing a fashion line inspired by the two million Canadians affected by osteoporosis TORONTO, Feb. 6, 2019  – Models clad in stylish bubble wrap strutted down the Toronto Fashion Week® x […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

ONTARIO OSTEOPOROSIS STRATEGY Ontario Osteoporosis Strategy The Ontario Osteoporosis Strategy represents the vision and coordinated efforts of many groups, including the Ministry of Health and Long-Term Care (MOHLTC), Ontario Women’s […]

No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]

SUPPORT RESOURCES Booklets, Brochures, Fact Sheets and Inserts English Resources Booklets & Fact Sheets Drug Treatments This four-page fact sheet focuses on medications used to treat osteoporosis. Contains detailed information […]